Vaccine Research · 2014 · 11 citations · 10 references
Life SciencesImmunologyInfectious DiseasesMolecular VirologyNanomaterialsVirologyNanomedicineNanoparticle SynthesisNanoparticle-based ImmunotechnologyVeterinary VaccinesViral VaccinesAntibodiesAntibody-mediated Viral NeutralizationAntibody-mediated Virus NeutralizationNanoparticle ImmunogenicityNanoparticlesNeutralizing Antibody AssaysRabies Virus
Nanoparticles have been considered as promising tools because of their high applicability. Recently, nanoparticles have been evaluated for their ability to increase the immune responses as adjuvants. Silver-nanoparticles (AgNPs) have shown promising results in enhancing Th-2 immune responses and to produce potent neutralizing antibodies. Neutralizing antibodies are considered as the main defense mechanism in preand post-exposure treatments of rabies disease. Therefore in this study, the effects of AgNPs in enhancing the immunogenicity of inactivated rabies virus were assessed. Methods: Different concentrations of AgNPs (0.2, 0.4, 0.6 and 0.8 mg/ml) were added to inactivated rabies virus. Mice were immunized by two intra-peritoneal injections of each concentration on days 1 and 7. The inactivated virus and Alum were used as negative and positive controls, respectively. Blood was collected from healthy and immunized mice, one week after the last immunization. Serum was isolated from each sample and the amounts of neutralizing antibodies were determined by Rapid Florence Focus Inhibition Test (RFFIT). The cytotoxicity of AgNPs was also assessed by in vitro MTT assay on J774A.1 cell line. Results: The results showed that 0.4, 0.6 and 0.8 mg/ml of AgNPs had significantly increased the immune responses compared to the control; however, 0.2 mg/ml of AgNPs did not show a significant effect. No cytotoxicity was observed for 0.001 and 0.01 mg/ml concentrations of AgNPs but cell viability was decreased significantly at 0.1 mg/ml concentration. Conclusion: It was shown that the virus-loaded AgNPsat 0.4 mg/ml concentration could raise the neutralizing antibodies against rabies virus in mice, but their adverse effect on cell viability excludes their use as an adjuvant.
10
Mechanism of action of licensed vaccine adjuvants
Elaine Tritto, Flaviana Mosca, Ennio De Gregorio · Vaccine · 2009 · 212 citations
Evaluation of the adjuvant effect of silver nanoparticles both in vitro and in vivo
Yingying Xu, Huan Tang, Jiahui Liu et al. · Toxicology Letters · 2013 · 105 citations
Selection of Adjuvants for Enhanced Vaccine Potency
Wei Wang, Manmohan Singh · World Journal of Vaccines · 2011 · 85 citations · Full text